MedTrace Logo

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

NCT00657514 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-08-15

No results posted yet for this study

Summary

After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will change compared to placebo in patients with chronic angina and peripheral arterial disease.

Conditions

  • Peripheral Arterial Disease
  • Angina

Interventions

DRUG

Ranolazine

500mg tablet po bid up to 1000mg (2 500mg tablets) po bid

DRUG

Placebo

1 tablet po bid up to 2 tablets po bid if tolerated

Sponsors & Collaborators

  • Colorado Prevention Center

    lead OTHER

Principal Investigators

  • Mark R Nehler, MD · The Univesity of Colorado at Denver

  • William R Hiatt, MD · Colorado Prevention Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00657514 on ClinicalTrials.gov